Skip to content
Colorectal Cancer Clinical Trials

Pittsburgh, Pennsylvania

Colorectal cancer clinical trials in Pittsburgh, PA

37 colorectal cancer studies are recruiting participants at sites in Pittsburgh as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Pittsburgh at a glance

  • 37 studies are recruiting at a site in Pittsburgh.
  • By phase: Phase 1 (9), Phase 1/2 (9), Phase 2 (5), Phase 2/3 (1), Phase 3 (8), No phase (4), Observational (1). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (22), university, hospital or other (12), government (3).
  • Most recent update to one of these records: November 16, 2026.

Studies recruiting in Pittsburgh

Basic details from each study's public record (the 30 most recently updated of 37). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Allegheny General Hospital · West Penn Hospital
    Registry record
    NCT05863195 · updated
  2. A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    UPMC Hillman Cancer Center ( Site 2024)
    Registry record
    NCT06997497 · updated
  3. Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT07228832 · updated
  4. Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

    • No phase
    • Ages 45 to 70
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    UPMC-Presbyterian Hospital
    Registry record
    NCT05080673 · updated
  5. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Allegheny General Hospital · UPMC Hillman Cancer Center · UPMC-Mercy Hospital
    Registry record
    NCT05174169 · updated
  6. Distance-Based Exercise to Preserve Function and Prevent Disability

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    UPMC Hillman Cancer Center · UPMC-Magee Womens Hospital · UPMC-Passavant Hospital
    Registry record
    NCT07059884 · updated
  7. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07397338 · updated
  8. Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Allegheny General Hospital · West Penn Hospital
    Registry record
    NCT05673148 · updated
  9. A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
    Registry record
    NCT06662786 · updated
  10. A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
    Registry record
    NCT06750094 · updated
  11. A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study sites
    Allegheny General Hospital Cancer Institute · Hillman Cancer Center
    Registry record
    NCT07284849 · updated
  12. Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT05803382 · updated
  13. Lead-212 PSV359 Therapy for Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 to 90
    • All sexes
    Sponsor
    Perspective Therapeutics
    Study site
    University of Pittsburgh Medical Center
    Registry record
    NCT06710756 · updated
  14. The Cancer of the Pancreas Screening-5 CAPS5)Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Johns Hopkins University
    Study site
    University of Pittsburgh
    Registry record
    NCT02000089 · updated
  15. Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT06654037 · updated
  16. A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Criterium, Inc.
    Study site
    UPMC / University of Pittsburgh Medical Center
    Registry record
    NCT06992258 · updated
  17. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kura Oncology, Inc.
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT06026410 · updated
  18. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Parabilis Medicines, Inc.
    Study site
    University of Pittsburgh Medical Center, Hillman Cancer Center
    Registry record
    NCT05919264 · updated
  19. Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Bicara Therapeutics
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT04429542 · updated
  20. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    PMV Pharmaceuticals, Inc
    Study site
    University of Pittsburgh Medical Center
    Registry record
    NCT04585750 · updated
  21. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #32
    Registry record
    NCT05176483 · updated
  22. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT05877599 · updated
  23. Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Phanes Therapeutics
    Study site
    University of Pittsburgh Medical Center (UPMC)
    Registry record
    NCT05482893 · updated
  24. Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Allegheny Health Network
    Registry record
    NCT06128551 · updated
  25. A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Aktis Oncology, Inc.
    Registry record
    NCT07020117 · updated
  26. A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    NSABP Foundation Inc
    Study sites
    Allegheny General Hospital · Magee-Womens Hospital of UPMC
    Registry record
    NCT07058012 · updated
  27. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

    • Phase 1/2
    • From 12 months, up to 30 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Children's Hospital of Pittsburgh of UPMC
    Registry record
    NCT04851119 · updated
  28. A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Kahr Bio Australia Pty Ltd
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07235293 · updated
  29. Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT05691491 · updated
  30. A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Coherus Oncology, Inc.
    Study site
    University of Pittsburg Medical Center _UPMC Hillman Cancer Center
    Registry record
    NCT06657144 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Ask about studies near Pittsburgh

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Pennsylvania

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call